The strong causal relationship between PAX3/7–FOXO1 fusion oncoproteins and alveolar rhabdomyosarcoma provides the rationale to employ therapeutic approaches targeting these fusion proteins. The gene discussed is FOXO1; the disease is rhabdomyosarcoma.